Cargando…

Efficacy of anti-vascular endothelial growth factor agents for treating neovascular age-related macular degeneration in vitrectomized eyes

PURPOSE: To evaluate the efficacy of intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents for treatment of neovascular age-related macular degeneration (nAMD) in vitrectomized eyes. METHODS: The medical records were reviewed of nAMD patients treated with anti-VEGF agents who previ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mun, Yongseok, Park, Kyu Hyung, Park, Sang Jun, Woo, Se Joon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8191940/ https://www.ncbi.nlm.nih.gov/pubmed/34111133 http://dx.doi.org/10.1371/journal.pone.0252006

Ejemplares similares

Intravitreal Brolucizumab for Neovascular Age-Related Macular Degeneration in a Vitrectomized Eye
por: Maggio, Emilia, et al.
Publicado: (2022)

Comparison of treatment methods for submacular hemorrhage in neovascular age-related macular degeneration: conservative versus active surgical strategy
por: Mun, Yongseok, et al.
Publicado: (2022)

Successful treatment of neovascular age-related macular degeneration following single bevacizumab failure using aflibercept in a vitrectomized eye
por: Hahn, Paul
Publicado: (2014)

Discontinuation of treatment and retreatment of neovascular age-related macular degeneration in the real-world: Bundang AMD cohort study report 5
por: Cho, Soo Chang, et al.
Publicado: (2023)

Long-term outcomes of ranibizumab vs. aflibercept for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy
por: Jin, Ki Won, et al.
Publicado: (2021)

Choroidal Blood Flow After Intravitreal Ranibizumab in Vitrectomized and Non-Vitrectomized Eyes with Diabetic Macular Edema
por: Pessoa, Bernardete, et al.
Publicado: (2021)

Comparison of Inflammatory and Angiogenic Factors in the Aqueous Humor of Vitrectomized and Non-Vitrectomized Eyes in Diabetic Macular Edema Patients
por: Liang, Youling, et al.
Publicado: (2021)

Evaluation of the Effect of Intravitreal Dexamethasone (Ozurdex(®)) Implant on Intraocular Pressure in Vitrectomized and Non-Vitrectomized Eyes with Macular Edema
por: Garlı, Murat, et al.
Publicado: (2021)

Case of Spontaneous Closure and Recurrence of Macular Hole in Vitrectomized Eye
por: Komi, Yuki, et al.
Publicado: (2023)

Descemet’s membrane endothelial keratoplasty in aphakic and vitrectomized eye
por: Karadag, Remzi, et al.
Publicado: (2020)

Vitrectomized versus non-vitrectomized eyes in diabetic macular edema response to ranibizumab—retinal layers thickness as prognostic biomarkers
por: Pessoa, Bernardete, et al.
Publicado: (2021)

Commentary: Treatment of postoperative cystoid macular edema in vitrectomized eyes: An enigma
por: Kohli, Piyush, et al.
Publicado: (2023)

Antivascular Endothelial Growth Factor Agents for Neovascular Age-Related Macular Degeneration
por: Zampros, Ilias, et al.
Publicado: (2012)

Evolution of macular atrophy in eyes with neovascular age-related macular degeneration compared to fellow non-neovascular eyes
por: Blazaki, Styliani, et al.
Publicado: (2023)

Macular hole developing in a post-vitrectomized eye and its surgical outcome
por: Rishi, Pukhraj, et al.
Publicado: (2013)

Effectiveness of Intravitreal Dexamethasone Implant Treatment for Diabetic Macular Edema in Vitrectomized Eyes
por: Özdemir, Hüseyin Baran, et al.
Publicado: (2019)

Comparison of Intravitreal Dexamethasone Implant and Ranibizumab in Vitrectomized Eyes with Diabetic Macular Edema
por: Wang, Jia-Kang, et al.
Publicado: (2021)

Subgroups and Features of Poor Responders to Anti-Vascular Endothelial Growth Factor Treatment in Eyes with Neovascular Age-Related Macular Degeneration
por: Barış, Mine Esen, et al.
Publicado: (2020)

One-Year Outcome of Aflibercept Intravitreal Injection in Vitrectomized Eyes with Diabetic Macular Edema
por: Tran, Thi Ha Chau, et al.
Publicado: (2021)

Two-Year Outcome of Aflibercept Intravitreal Injection in Vitrectomized Eyes with Diabetic Macular Edema
por: Tran, Thi Ha Chau, et al.
Publicado: (2022)

Positional Intraocular Pressure of Vitrectomized and Normal Fellow Eyes
por: Lee, Jae Hyuck, et al.
Publicado: (2018)

Phacoemulsification Surgery in Eyes with Neovascular Age-Related Macular Degeneration
por: Grixti, Andre, et al.
Publicado: (2014)

Investigation of the Trend of Selecting Anti-Vascular Endothelial Growth Factor Agents for the Initial Treatment of Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy
por: Kim, Jae-Hui, et al.
Publicado: (2021)

Macular hole formation and spontaneous closure following neodymium-doped yttrium aluminum garnet capsulotomy in a vitrectomized eye
por: Park, Jongyeop, et al.
Publicado: (2016)

Dislocated Intraocular Lens Extraction and Iris-Claw Lens Implantation in Vitrectomized and Non-vitrectomized Eyes
por: Ersöz, M. Giray, et al.
Publicado: (2019)

Associations of Variation in Retinal Thickness With Visual Acuity and Anatomic Outcomes in Eyes With Neovascular Age-Related Macular Degeneration Lesions Treated With Anti–Vascular Endothelial Growth Factor Agents
por: Evans, Rebecca N., et al.
Publicado: (2020)

Comparison of the Effect of Intravitreal Dexamethasone Implant in Vitrectomized and Nonvitrectomized Eyes for the Treatment of Diabetic Macular Edema
por: Çevik, Sadık Görkem, et al.
Publicado: (2018)

Office-based intravitreal injection of expansile gas for management of macular hole in previously vitrectomized eyes
por: Apolinario, Michael A., et al.
Publicado: (2019)

Intravitreal Tissue Plasminogen Activator Injection for Treatment-Resistant Diabetic Macular Edema of the Vitrectomized Eye
por: Aoki, Ren, et al.
Publicado: (2021)

Vascular Endothelial Growth Factor Antagonists: Promising Players in the Treatment of Neovascular Age-Related Macular Degeneration
por: Hussain, Rehan M, et al.
Publicado: (2021)

Ahmed Glaucoma Valve Implantation in Vitrectomized Eyes
por: Erçalık, Nimet Yeşim, et al.
Publicado: (2018)

Prediction of anti-vascular endothelial growth factor agent-specific treatment outcomes in neovascular age-related macular degeneration using a generative adversarial network
por: Moon, Sehwan, et al.
Publicado: (2023)

Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor
por: Moon, Da Ru Chi, et al.
Publicado: (2015)

Choroidal endothelial and macrophage gene expression in atrophic and neovascular macular degeneration
por: Voigt, Andrew P, et al.
Publicado: (2022)

Changes in Fundus Autofluorescence after Anti-vascular Endothelial Growth Factor According to the Type of Choroidal Neovascularization in Age-related Macular Degeneration
por: Lee, Ji Young, et al.
Publicado: (2016)

Laser and anti-vascular endothelial growth factor treatment for drusenoid pigment epithelial detachment in age-related macular degeneration
por: Kim, Min Seok, et al.
Publicado: (2020)

Inflammatory Factors of Macular Atrophy in Eyes With Neovascular Age-Related Macular Degeneration Treated With Aflibercept
por: Sato, Tomohito, et al.
Publicado: (2021)

Impact of Prophylactic Ranibizumab to Prevent Neovascular Age-Related Macular Degeneration on Eyes With Intermediate Age-Related Macular Degeneration
por: Chan, Clement K., et al.
Publicado: (2023)

Long-Term Visual Outcomes for a Treat and Extend Anti-Vascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration
por: Mrejen, Sarah, et al.
Publicado: (2015)

Rapid macular hole formation and closure in a vitrectomized eye following rhegmatogenous retinal detachment repair
por: Ranjan, Ratnesh, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_d3dp4tkh0qr0ie59buhq16oim0